Healthcare

AFT Pharmaceuticals Limited (ASX:AFP)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Pharmaceuticals

Market Price : AUD 4.030.14 (3.599%)

(as on 2021-09-28 09:55:05)

Market Cap : AUD 421.856 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
3.89 4.04 4.03 4.03L 4.04 H 3.64L 5.25 H
Last Trade 4.03
Change% 3.5990
52 W H/L 5.25/3.64
EBITDA 11.328 M
NPAT After Abnormal Items 7.144 M
Equity 33.589 M
ROE% 21.27%
Total Liabilities 62.925 M
Total Revenue 104.973 M
Cash and Cash Equivalents 2.946 M

Stock Information

Share price 4.03
Market Cap 421.856 M
Price/Gross Cash Flow 54.27
Dividend Yield Excluding Special 0.00%
Ending Shares 104.584 M
52-Week Range 3.64-5.25
P/E ratio 53.476
Sector P/E --
EPS 6.92
EV/EBITDA 42.46
Net Profit Margin (%) 6.88%
Gross Cash Flows Per Share 0.08
Net Gearing 106.61%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 1.870
Net Tangible Asset (NTA) 0.03
Sales Per Share 1.01
Book Value Per Share 0.32

Announcements

Heading Date/Time
AFT further extends Maxigesic footprint strengthens EU  21/09/2021 7:31AM
Change of Capital notice  06/09/2021 9:18AM
ASM 2021 results  06/08/2021 12:16PM
ASM presentation  06/08/2021 7:44AM
ASM chairs address  06/08/2021 7:38AM
New clinical study Novaliq NovaTears Omega-3 eye drops  29/07/2021 7:30AM
Application for quotation of securities - AFP  14/07/2021 4:09PM
D&O Ongoing Disclosure - Louise Clayton  14/07/2021 3:59PM
Capital Change Notice - Issue of ordinary shares  14/07/2021 3:51PM
Maxigesic Oral Liquid gets first regulatory approval  14/07/2021 9:20AM
Maxigesic IV launches in Germany and Austria  08/07/2021 7:30AM
ASM 2021 Proxy form  08/07/2021 7:30AM
Notice of Annual Meeting of Shareholders 2021  06/07/2021 7:45AM
Application for quotation of securities - AFP  24/06/2021 11:18AM
Appendix 2A  23/06/2021 9:02AM
Capital Change Notice  21/06/2021 9:08AM
FY 2021 AFT Financial Presentation  24/05/2021 7:31AM
FY2021 Annual Report  24/05/2021 7:31AM
FY2021 Announcement App 2  24/05/2021 7:30AM
FY2021 Announcement  24/05/2021 7:30AM
Appendix 2A  12/05/2021 2:02PM
AFT extends Maxigesic IV license in South America  05/05/2021 7:44AM
AFT Pharmaceuticals to announce full year results on Monday  04/05/2021 7:30AM
Capital change notice - issue of shares  03/05/2021 12:51PM
AFT licenses Maxigesic IV in the US  28/04/2021 7:30AM
Crystawash Extend distribution in UAE, Kuwait, Oman and Ken  12/04/2021 8:52AM
AFT secures new partners in Poland and Greece  07/04/2021 7:30AM
AFT updates earnings guidance  01/04/2021 7:30AM
AFT licenses Pascomer for Europe  17/03/2021 9:14AM

Similar Companies

Related Articles

Load More

About Company

AFT Pharmaceuticals Limited is an ASX-listed health care company which develops, licenses and sells a range of medical products while providing innovative health solutions. Its major medical products are aimed at pain-relief, eye care and cold and flu treatment. The company uses licenses as a cost-effective revenue generation method to get its product distributed across overseas market.

Corporate Information

company address Level 1, Neilson Building, 129 Hurstmere Road, AUCKLAND, ., NEW ZEALAND, .

company phone+64 9 488 0232

company websitehttp://www.aftpharm.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/03/2021 -- 0.000 0.00%
30/03/2020 -- 0.000 0.00%
30/03/2019 -- 0.000 0.00%
30/03/2018 -- 0.000 0.00%
30/03/2017 -- 0.000 0.00%
30/03/2016 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-05-23 2022
Report (Prelim) 2022-05-23 2022
Report (Interim) 2021-11-18 2021

Financials

Breakdown 30/03/2021 30/03/2020 30/03/2019 30/03/2018 30/03/2017
Trading Revenue 103.609 M 102.604 M 81.279 M 75.035 M 63.057 M
Other Revenue 1.364 M 10.408 M 2.387 M 2.277 M 2.573 M
Total Revenue 104.973 M 113.012 M 83.666 M 77.312 M 65.629 M
Interest Income 3,672 21,448 40,222 117,414 316,894
Interest Expenses -3.43 M -8.142 M -8.061 M -2.491 M -3.542 M
Expenses -93.293 M -100.803 M -77.503 M -86.516 M -79.349 M
EBITDA 11.68 M 12.208 M 6.163 M -9.204 M -13.72 M
Depreciation and Amortization -1.013 M -1.072 M -305,497 -319,368 -297,716
Depreciation -751,858 -793,604 -110,132 -118,354 -130,593
Amortisation -261,635 -278,833 -195,364 -201,014 -167,123
EBIT 10.666 M 11.136 M 5.857 M -9.524 M -14.017 M
Pre Tax Profit 7.24 M 3.016 M -2.163 M -11.897 M -17.242 M
Tax Expense -96,392 -180,364 -160,888 -54,480 -52,968
Net Profit After Tax 7.144 M 2.835 M -2.324 M -11.952 M -17.295 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 -386,718 0
Net Abnormal Items 0 9.539 M 0 0 502,283
Reported Net Profit After Abnormal Items 7.144 M 12.374 M -2.324 M -11.952 M -16.793 M
Ending Shares 104.584 M 97.309 M 97.308 M 97.308 M 96.835 M
Weighted Average Shares 103.297 M 97.309 M 97.308 M 97.249 M 97.112 M
EPS After Abnormal Items (cents) 6.92 12.72 -2.39 -12.69 -17.29
Breakdown 30/03/2021 30/03/2020 30/03/2019 30/03/2018 30/03/2017
Total Current Assets 62.335 M 53.949 M 49.091 M 45.38 M 49.37 M
Total Non Current Assets 34.178 M 30.921 M 11.812 M 7.788 M 3.809 M
Total Assets 96.513 M 84.871 M 60.903 M 53.168 M 53.179 M
Total Current Liabilities 29.47 M 24.473 M 56.028 M 17.478 M 14.005 M
Total Non Current Liabilities 33.455 M 43.575 M 0 28.794 M 21.394 M
Total Liabilities 62.925 M 68.048 M 56.028 M 46.272 M 35.398 M
Net Assets 33.589 M 16.823 M 4.876 M 6.896 M 17.781 M
Breakdown 30/03/2021 30/03/2020 30/03/2019 30/03/2018 30/03/2017
Net Operating Cash 688,515 14.505 M 1.022 M -10.242 M -17.408 M
Net Invested Cash -5.72 M -6.398 M -4.677 M -5.5 M -1.459 M
Net Financing Cash Flows 2.315 M -8.89 M 3.565 M 7.139 M 8.258 M
End Cash Position 2.946 M 5.966 M 6.623 M 6.359 M 14.594 M
Beginning Cash 5.617 M 6.743 M 6.483 M 14.94 M 25.621 M
Exchange Rate Adjustments 44,983 4,874 229,841 22,543 -417,351
Other Cash Adjustments 0 0 0 0 0
Ending Cash 2.946 M 5.966 M 6.623 M 6.359 M 14.594 M

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or ‘regulated financial advice’ under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ) at www.morningstar.com.au/s/fsg.pdf and www.morningstar.com.au/s/fapds.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyright and published under license from ASX Operations Pty Ltd ACN 004 523 782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK